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   ABSTRACT 
  Objectives      To identify baseline disease-related 
predictors in patients with early inﬂ  ammatory polyarthritis 
(IP) for starting subsequent biological therapy and to 
determine if patients who failed their ﬁ  rst non-biological 
disease-modifying antirheumatic drug (DMARD) within 
6 months were more likely to need biological therapy.   
  Methods      Patients with early IP recruited between 
1990 and 1994 (cohort 1) and between 2000 and 2004 
(cohort 2) in the Norfolk Arthritis Register were included 
in this study. The association between possible predictors 
with the start of biological therapy was assessed using 
Cox proportional hazards regression models.   
  Results      32/407 (7.9%) patients in cohort 1 and 45/416 
(10.8%) patients in cohort 2 received biological therapy 
during follow-up. In both cohorts, anti-citrullinated protein 
antibody (ACPA) positivity (cohort 1, HR 7.62, 95% CI 
2.46 to 23.58; cohort 2, HR 4.68, 95% CI 2.23 to 9.78) 
was the strongest predictor for starting biological therapy. 
In cohort 2, younger patients (HR 0.97, 95% CI 0.95 to 
0.99) and patients who failed their ﬁ  rst non-biological 
DMARD within 6 months due to inefﬁ  cacy were also 
more likely to receive biological therapy (HR 2.35, 95% CI 
1.05 to 5.27).   
  Conclusion      Patients with early IP who are ACPA 
positive, are younger or who fail their ﬁ  rst non-biological 
DMARD due to inefﬁ  cacy within 6 months are more likely 
to  need  biological  therapy.      
  The introduction of biological therapies has been 
an important therapeutic advance in the treat-
ment of patients with rheumatoid arthritis (RA) 
making the achievement of sustained remis-
sion and retarded radiographic progression more 
feasible.    1–3    In the UK, based on recommendations 
by the National Institute for Health and Clinical 
Excellence (NICE), the use of biological therapies 
is restricted to patients with active RA, deﬁ  ned as 
a 28-joint disease activity score (DAS28) greater 
than 5.1 despite previous therapy with at least two 
disease-  modifying antirheumatic drugs (DMARD), 
one of which should be methotrexate.    4        5    
  It is important to be able to identify early in dis-
ease, patients who will need biological therapy later 
on, ie, have a worse disease course, so that they 
can be fast-tracked in the future to start biological 
therapies sooner. In one US retrospective cohort 
study, starting biological therapy was signiﬁ  cantly 
associated with worse functional disability in the 
preceding 6 months, treatment with steroids and 
non-biological DMARD, younger age and lower 
income.    6    However, the mean disease duration at 
entry to the database was 16.2 years and infor-
mation on disease activity early in the disease or 
genetic markers was not available in the study. 
  Using a primary-care based incidence register 
of patients with early inﬂ  ammatory polyarthritis 
(IP), the objectives of this study were to identify 
baseline disease-related predictors in patients with 
early IP for starting biological therapy and to deter-
mine if patients who failed their ﬁ  rst non-biological 
DMARD within 6 months of starting the ﬁ  rst non-
biological DMARD were more likely to need bio-
logical therapy later on. 
  PATIENTS  AND  METHODS 
    Clinical assessments and study population 
  Consecutive patients aged over 16 years with early 
IP from the Norfolk Arthritis Register (NOAR), 
recruited between 1990 and 1994 (cohort 1) or 
between 2000 and 2004 (cohort 2), were included in 
this study. Cohort 1 developed their IP in the prebio-
logical era and cohort 2 in the   biological era. Details 
of NOAR have been published   previously.    7    Brieﬂ  y, 
patients with swelling in two or more joints that 
lasted 4 weeks or longer were referred to NOAR. 
At baseline, patients were seen by a research nurse. 
Clinical assessments included the evaluation of the 
number of swollen and tender joints. The DAS28 
based on three components including C-reactive 
protein (DAS28(3)  CRP  ) was calculated based on the 
28 swollen and tender joint count and CRP value. 
Blood was collected to measure rheumatoid fac-
tor (RF; positive >40 UL), anti-citrullinated protein 
antibody (ACPA; ≥5 U/ml (Axis-Shield DIASTAT 
Kit; Axis-Shield, Dundee, Scotland  )), CRP and for 
genetic analysis. Human leucocyte antigen geno-
typing was carried out as described previously and 
subtyping at the  HLA-DRB1   locus was performed to 
identify the presence of the shared epitope (SE).    8    In 
addition, patients completed the British version of 
the health assessment questionnaire (HA).    9    Clinical 
follow-up assessments were carried out annually 
for 3 years and then at 5, 7, 10, 12 and 15 years. 
  Patients with a symptom duration of 24 months 
or less at baseline, who had started a non-biological 
DMARD (except oral glucocorticoids) and had at 
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DMARD. For all models, patients were followed until the date 
of starting biological therapy or the last follow-up visit if no 
biological therapy was started. Subsequently, univariate regres-
sion analyses were restricted to patients who fulﬁ  lled the 1987 
American College of Rheumatology (ACR) criteria for RA cumu-
latively at any of the follow-up visits. All analyses were carried 
out using STATA release 10.     
  RESULTS 
  Patient  characteristics 
  At baseline, the median symptom duration was 5 (3–10) months 
in cohort 1 and 7 (5–11) months in cohort 2; and 34% of cohort 1 
and 65% of cohort 2 (previously) used non-biological DMARD 
and 7% and 31%, respectively, (previously) used oral glucocor-
ticoids. The median follow-up duration since symptom onset 
was 180 (102–187) months in cohort 1 and 68 (61–89) months 
in cohort 2. The median time between symptom onset and 
start of the ﬁ  rst non-biological DMARD was 9 (4–19) months in 
cohort 1 and 6 (4–12) months in cohort 2. Fifteen (3.7%) patients 
in cohort 1 and 36 (8.7%) patients in cohort 2 stopped taking the 
ﬁ  rst non-biological DMARD within 6 months due to inefﬁ  cacy.   
    The use of biological therapy 
  Thirty-two (7.9%) patients in cohort 1 and 45 (10.8%) patients 
in cohort 2 started biological therapy after a median time since 
symptom onset of 143 (118–159) and 47 (24–69) months, respec-
tively (  table 1  ). The median age at symptom onset of patients 
who subsequently used biological therapy was 47 (35–55) 
years in cohort 1 and 50 (41–55) years in cohort 2 compared 
with, respectively, 54 (44–65) years in cohort 1 and 58 (48–70) 
years in cohort 2 in those who did not use biological therapy 
(  table 2  ). Eighty-one per cent (cohort 1) and 70.3% (cohort 2) 
who used biological therapy were ACPA positive at baseline 
compared with 42.3% (cohort 1) and 36.2% (cohort 2) in those 
who did not use biological therapy; 33.3% (cohort 1) and 22.0% 
least 6 months follow-up after the start date, and with at least 
one total follow-up datum available were included in this study. 
Only patients who were non-biological DMARD and biological 
naive at symptom onset were included. We excluded patients 
who had participated in a clinical trial in whom the possible 
use of non-biological DMARD and biological therapies was 
therefore unknown (n=24). This study was approved by the 
Norwich Research Ethics Committee and all patients gave writ-
ten informed consent.   
    Use of non-biological DMARD and biological therapies 
  The start and stop dates and reason for stopping non-  biological 
DMARD and biological therapies was recorded at every visit. 
Based on information from medical notes or given by the patient, 
the reasons for stopping non-biological DMARD were deﬁ  ned 
as: (1) adverse reaction; (2) inefﬁ  cacy; (3) disease remission; (4) 
planned course complete; (5) lack of compliance or (6) other. 
Non-biological DMARD failure within 6 months due to inef-
ﬁ   cacy was deﬁ   ned as: ﬁ   rst non-biological DMARD stopped 
due inefﬁ  cacy within 6 months and/or second non-  biological 
DMARD added/started within 6 months of starting the ﬁ  rst 
non-biological DMARD.   
  Statistical  analysis 
  Data were analysed separately for cohorts 1 and 2. The associa-
tion of baseline disease-related characteristics and the start of 
the ﬁ  rst biological therapy was assessed using Cox proportional 
hazards regression models. HR (95% CI) were adjusted for age 
at symptom onset, gender and symptom duration at baseline. 
Variables with a p value less than 0.10 were then included in 
a multivariate Cox proportional hazards regression model to 
determine the independent contribution of each variable. The 
association with failure of the ﬁ  rst non-biological DMARD due 
to inefﬁ  cacy was analysed separately. For this analysis the sur-
vival time started 6 months after starting the ﬁ  rst non-biological 
  Table  1          Baseline characteristics cohort 1 and cohort 2   
   N    Cohort 1 (n=407)   N    Cohort 2 (n=416) 
Age at symptom onset (years) 407 53 (43–64) 416 57 (48–69)
Gender (female) 407 250 (61%) 416 269 (65%)
Baseline visit
  Symptom duration (months) 407 5.4 (3.0–10.0) 416 6.7 (4.5–11.4)
  RA (1987 ACR criteria) 407 255 (62.7%) 416 220 (52.9%)
  No of swollen joints 407 7 (3–14) 416 3 (1–7)
  No of tender joints 407 7 (2–14) 416 3 (0–8)
  CRP (mg/L) 336 10 (2–27) 363 12 (4–26)
 DAS28(3)  CRP  336 4.5 (3.5–5.5) 363 3.7 (2.8–4.7)
  HAQ score 398 1.0 (0.5–1.6) 408 1.0 (0.5–1.8)
  RF (positive) 368 160 (43.5%) 371 155 (41.8%)
  ACPA (positive) 288 130 (45.1%) 341 136 (39.9%)
  SE (no of alleles)
  0 351 115  (32.8%) 371 135  (36.4%)
  1   170  (48.4%)   178  (48.0%)
  2   66  (18.8%)   58  (15.6%)
  Previous or current DMARD use 407 142 (34%) 416 269 (65%)
  Previous or current steroid use 407 29 (7%) 416 130 (31%)
 Smoking        
    Never smoked 407 129 (31.7%) 377 113 (30.0%)
  Ex-smoker   162  (39.8%)   166  (44.0%)
  Current  smoker   116 (28.5%)   98 (26.0%)
      Patients in cohort 1 were recruited between 1990 and 1994 and patients in cohort 2 were recruited between 2000 and 2004. Values 
are median (IQR) for continuous variables and numbers (%) for categorical variables. 
  ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28(3)  CRP ,  28-joint 
disease activity score based on three components including CRP; DMARD, disease-modifying antirheumatic drug; HAQ, health 
assessment questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; SE, shared epitope.     
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associated with the start of biological therapy in cohort 1, but 
not in cohort 2. In cohort 2, current smokers compared with 
non-smokers, but not ex-smokers, were more likely to start bio-
logical therapy. Neither functional disability nor DAS28(3)  CRP   
measured at baseline was associated with the start of biologi-
cal therapy. However, in cohort 2 the number of swollen joints 
was associated with starting biological therapy (HR 1.06, 95% 
CI 1.00 to 1.12) as was failing the ﬁ  rst non-biological DMARD 
within 6 months due to inefﬁ  cacy (HR 2.35, 95% CI 1.05 to 
5.27); associations not observed in cohort 1.   
  In multivariate regression analysis ACPA positivity (HR 6.68, 
95% CI 1.75 to 25.41), fulﬁ  lment of ACR 1987 criteria (HR 4.15, 
95% CI 1.14 to 15.02) and younger age (HR 0.96, 95% CI 0.92 
to 1.00) were signiﬁ  cant independent predictors for starting bio-
logical therapy in cohort 1. In cohort 2, the signiﬁ  cant indepen-
dent predictors were ACPA positivity (HR 4.19, 95% CI 1.75 to 
10.02), younger age (HR, 0.94, 95% CI 0.92 to 0.97) and higher 
number of swollen joints (HR 1.11, 95% CI 1.02 to 1.22). 
  When restricting the univariate analyses to patients who 
fulﬁ  lled the 1987 ACR criteria for RA cumulatively during fol-
low-up (n=378 in cohort 1 and n=340 in cohort 2), ACPA positiv-
ity remained the strongest predictor in both cohorts (  table 3  ). In 
cohort 2, the number of swollen joints measured at baseline and 
failing the ﬁ  rst DMARD due to inefﬁ  cacy were no longer predic-
tors for starting biological therapy. The signiﬁ  cant association 
(cohort 2) of biological therapy users versus 17.5% (cohort 1) 
and 14.9% (cohort 2) of biological therapy non-users carried 
two SE alleles.     
  Inﬂ   iximab was the most common ﬁ  rst  biological  therapy 
in cohort 1 (44%), whereas in cohort 2 this was adalimumab 
(51%). On average, patients in cohort 1 used 3.3 (SD 1.4) and 
patients in cohort 2 used 3.0 (SD 1.3) non-biological DMARD 
before receiving biological therapy.   
    Predictors for starting biological therapy 
  In both cohorts, ACPA positivity was the strongest predic-
tor for starting biological therapy (cohort 1, HR 7.62, 95% CI 
2.46 to 23.58; cohort 2, HR 4.66, 95% CI 2.23 to 9.78) (  table 3  ). 
Compared with the carriage of no alleles, those with two cop-
ies of SE were more likely to start biological therapy (cohort 
1, HR 3.07, 95% CI 1.15 to 8.17; cohort 2, HR 3.25, 95% CI 
1.25 to 8.47). However, in cohort 2, the association between 
homozygosity for the SE versus carrying one or no SE alleles 
was no longer signiﬁ  cant. Younger patients were more likely to 
receive biological therapy in cohort 2 (HR 0.97, 95% CI 0.95 to 
0.99). A similar association was seen in cohort 1, but this did 
not reach statistical signiﬁ  cance. There was a non-signiﬁ  cant 
trend towards an association between female gender and the 
start of biological therapy in both cohorts. RF positivity and a 
diagnosis of satisfying the 1987 ACR criteria for RA were both 
  Table  2          Baseline characteristics and follow-up data on non-biological DMARD use of biological therapy-naive patients and patients who started to 
use biological therapy   
 
 Cohort  1   Cohort  2 
 Biological  therapy-naive 
group (n=375) 
 Biological  therapy 
group (n=32) 
 Biological  therapy-naive 
group (n=371) 
 Biological  therapy 
group (n=45) 
Age at symptom onset (years) 54 (44–65) 47 (35–55) 58 (48–70) 50 (41–55)
Gender (female) 224 (60%) 26 (81%) 232 (63%) 37 (82%)
Baseline characteristics
  Symptom duration (months) 5.4 (3.0–9.7) 5.4 (3.3–12.9) 6.7 (4.4–11.7) 6.4 (4.6–8.7)
  RA (1987 ACR criteria) 230 (61.3%) 25 (78.1%) 194 (52.3%) 26 (57.8%)
  No of swollen joints 8 (2–14) 5 (3–12) 3 (1–7) 4 (1–7)
  No of tender joints 7 (2–14) 5 (2–10) 3 (0–8) 5 (1–8)
  CRP (mg/L) 10 (2–27) 10 (4–23) 12 (4–25) 16 (3–36)
 DAS28(3)  CRP  4.5 (3.5–5.5) 4.3 (3.2–5.4) 3.7 (2.8–4.6) 4.4 (3.0–5.0)
  HAQ score 1 (0.5–1.6) 1.1 (0.5–1.5) 1.0 (0.5–1.6) 1.1 (0.4–1.9)
  RF (positive) 142 (42.0%) 18 (60.0%) 139 (41.5%) 16 (44.4%)
  ACPA (positive) 113 (42.3%) 17 (81.0%) 110 (36.2%) 26 (70.3%)
 SE
    0 allele 108 (33.6%) 7 (23.3%) 127 (38.5%) 8 (19.5%)
    1 allele 157 (48.9%) 13 (43.3%) 154 (46.7%) 24 (58.5%)
    2 alleles` 56 (17.5%) 10 (33.3%) 49 (14.9%) 9 (22.0%)
 Smoking
    Never smoked 116 (30.9%) 13 (40.6%) 104 (31.3%) 9 (20.0%)
    Ex-smoker 153 (40.8%) 9 (28.1%) 149 (44.9%) 17 (37.8%)
    Current smoker 106 (28.3%) 10 (31.3%) 79 (23.8%) 19 (42.2%)
Follow-up data
  Follow-up duration (months) 168 (96–186) 188 (182–193) 68 (60–88) 70 (64–91)
  Time until starting ﬁ  rst DMARD since symptom onset (months) 9 (4–19) 10 (5–16) 6 (4–12) 7 (4–8)
  Time until starting ﬁ  rst biological therapy since symptom onset (months)   143 (118–159)   47 (24–69)
  First prescribed biological therapy
  Etanercept   11  (34%)   12  (27%)
  Inﬂ   iximab   14  (44%)   10  (22%)
  Adalimumab   6  (19%)   23  (51%)
  Rituximab   1  (3%)   0
  No of non-biological DMARD before start ﬁ  rst biological therapy   3.3 (1.4)   3.0 (1.3)
  Used steroids before starting biological agent (yes)   21 (66%)   23 (51%)
      Patients in cohort 1 were recruited between 1990 and 1994 and patients in cohort 2 were recruited between 2000 and 2004. Values are median (IQR) or mean (SD) for continuous 
variables and numbers (%) for categorical variables. 
  ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28(3)  CRP  , 28-joint disease activity score based on three components 
including CRP; DMARD, disease-modifying antirheumatic drug; HAQ, health assessment questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; SE, shared epitope.     
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DAS28(3)  CRP   or functional disability at baseline, factors often 
associated with a worse disease course, with the need to start 
biological therapy. We did not look at the cumulative disease 
activity, which may be an independent predictor for starting 
biological therapy. 
  Patients in cohort 2 who failed their ﬁ  rst  non-biological 
DMARD in the ﬁ  rst 6 months due to inefﬁ  cacy were more likely 
to receive biological therapy. This association is probably not 
observed in cohort 1 because biological therapy was not avail-
able until later in the disease. In a previous study from NOAR, 
we found that patients who discontinued their ﬁ  rst treatment 
within 6 months experienced more deterioration in physical 
functioning in the long term.    23    Given these ﬁ  ndings, it may be 
appropriate to fast-track these patients for biological therapy as 
soon as they have failed their ﬁ  rst non-biological DMARD for 
inefﬁ  cacy. 
  Only one other study has looked at predictors of starting bio-
logical therapy. In the US ARAMIS database high levels of func-
tional disability were associated with the initiation of biological 
therapy.    6    In both the US study and our study, biological thera-
pies were more often prescribed to younger patients. In general, 
there seems to be a trend towards less prescribing of non-bio-
logical DMARD and biological therapies in older patients,    24        25    
despite the fact that there is no difference in efﬁ  cacy or toler-
ability of more aggressive treatment strategies in patients aged 
under 65 years than in those aged 65 years or older.    26    
  This study comprised patients with IP recruited to a primary 
care-based inception cohort. Some people may argue that the dis-
ease course and applied treatment strategies may differ between 
patients with IP and RA and that biological therapy may only be 
prescribed to patients with RA. In our study population, 76/77 
(98.7%) patients using biological therapy fulﬁ  lled the criteria for 
of two copies of SE and failing the ﬁ  rst non-biological DMARD 
with starting biological therapy previously observed in cohort 2 
did not quite reach statistical signiﬁ  cance in the RA population 
(respectively, p=0.062 and p=0.051).     
  DISCUSSION 
  In this primary care-based inception cohort of patients with 
recent-onset IP who used at least one non-biological DMARD 
during follow-up, 7.9% of patients who were registered in the 
prebiological therapy era (cohort 1) and 10.8% of patients who 
were registered in the biological therapy era (cohort 2) received 
biological therapies within a median of 11.2 and 3.9 years from 
symptom onset, respectively. For patients in cohort 1, biological 
therapies only became available 5–10 years after registration in 
the NOAR cohort. Registration into cohort 2 started at approxi-
mately the same time as biological therapies became available in 
the UK. It, therefore, seems appropriate to show the results of 
these two cohorts separately. 
  A positive ACPA, measured at baseline, was the strongest 
predictor for starting biological therapy in both cohorts. The 
ACPA status was not known to the physician at the time treat-
ment was started, and so cannot have directly inﬂ  uenced treat-
ment decisions. Previous studies have shown that ACPA is a 
marker of disease severity    10    and is strongly associated with joint 
damage,    11–14    independent of RF status. The genetic contribution 
of SE to RA susceptibility    15        16    and the production of ACPA    17–19    
is well established. The linkage between SE and disease pro-
gression has, however, been investigated less.    20–22    In univariate 
analysis, but not multivariate regression analysis, we found in 
both cohorts that, compared with the carriage of no alleles of SE, 
carriers of two copies of SE were more likely to start biological 
therapy. Interestingly, we did not ﬁ  nd an association between 
  Table  3         Predictors for starting biological therapy in respectively the ﬁ  rst and second cohort   
 
  Cohort 1 (1990–4)    Cohort 2 (2000–4) 
  Total study population (n=407)    RA population (n=378)    Total study population (n=416)    RA population (n=340) 
  HR (95% CI)    HR (95% CI)    HR (95% CI)    HR (95% CI) 
Age at symptom onset 0.98 (0.96 to 1.01) 0.98 (0.95 to 1.00) 0.97 (0.95 to 0.99) 0.96 (0.94 to 0.98)
Female gender 2.23 (0.91 to 5.47) 2.15 (0.87 to 5.27) 2.09 (0.97 to 4.51) 1.76 (0.81 to 3.81)
Baseline variables:
  Symptom duration (per month) 1.04 (0.98 to 1.11) 1.04 (0.98 to 1.11) 0.97 (0.91 to 1.02) 0.96 (0.91 to 1.02)
  RA (1987 criteria) 2.52 (1.08 to 5.91) 2.02 (0.87 to 4.72) 1.51 (0.82 to 2.79) 0.99 (0.53 to 1.82)
  No of swollen joints 1.00 (0.94 to 1.05) 0.98 (0.93 to 1.04) 1.06 (1.00 to 1.12) 1.04 (0.98 to 1.09)
  No of tender joints 0.97 (0.92 to 1.02) 0.97 (0.92 to 1.02) 1.02 (0.98 to 1.06) 1.01 (0.97 to 1.06)
  CRP (mg/L) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01)
 DAS28(3)  CRP  1.05 (0.79 to 1.41) 1.00 (0.74 to 1.33) 1.28 (0.99 to 1.66) 1.17 (0.90 to 1.52)
  HAQ score 1.15 (0.68 to 1.96) 1.08 (0.64 to 1.84) 1.45 (0.95 to 2.21) 1.35 (0.88 to 2.07)
  Positive RF 2.78 (1.31 to 5.90) 2.62 (1.24 to 5.54) 1.32 (0.68 to 2.58) 1.09 (0.56 to 2.16)
  Positive ACPA status 7.62 (2.46 to 23.58) 6.63 (2.17 to 20.22) 4.68 (2.23 to 9.78) 3.74 (1.76 to 7.92)
  Shared epitope, no of alleles
  0 1 1 1 1
    1 1.32 (0.52 to 3.34) 1.22 (0.49 to 3.07) 2.44 (1.09 to 5.46) 2.15 (0.96 to 4.79)
    2 3.07 (1.15 to 8.17) 2.92 (1.10 to 7.76) 3.25 (1.25 to 8.47) 2.60 (1.00 to 6.77)
 Smoking  status
  Non-smoker 1 1 1 1
    Ex-smoker 0.75 (0.32 to 1.79) 0.78 (0.33 to 1.85) 1.88 (0.83 to 4.22) 2.16 (0.96 to 4.90)
    Current smoker 1.14 (0.49 to 2.63) 1.28 (0.55 to 1.85) 3.71 (1.66 to 8.30) 3.74 (1.66 to 8.41)
Treatment effect
  DMARD failure due to inefﬁ  cacy* 0.83 (0.11 to 6.10) 0.80 (0.11 to 5.86) 2.35 (1.05 to 5.27) 2.16 (0.96 to 4.85)
      Patients in cohort 1 were recruited between 1990 and 1994 and patients in cohort 2 were recruited between 2000 and 2004. HR (95% CI) age at symptom onset adjusted for gender 
and symptom duration; HR (95% CI) gender adjusted for age at symptom onset and symptom duration; HR (95% CI) symptom duration adjusted for age at symptom onset and gender; 
all other baseline variables adjusted for age at symptom onset, gender and symptom duration. 
  *Unadjusted HR (95% CI).
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28(3)  CRP  , 28-joint disease activity score based on three components including CRP; DMARD, disease-modifying 
antirheumatic drug; HAQ, health assessment questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.     
14_annrheumdis148106.indd   1431 14_annrheumdis148106.indd   1431 6/16/2011   6:53:57 PM 6/16/2011   6:53:57 PMExtended report
Ann Rheum Dis 2011;70:1428–1432. doi:10.1136/ard.2010.148106 1432
    9 .        Kirwan    JR,      Reeback    JS.      Stanford  Health  Assessment  Questionnaire  modiﬁ   ed 
to assess disability in British patients with rheumatoid arthritis.         Br J Rheumatol   
  1986  ;  25  :  206 – 9 .  
  10.       Farragher    TM,      Lunt    M,      Plant    D,     et al.       Beneﬁ  t of early treatment in inﬂ  ammatory 
polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those 
without  antibodies.      Arthritis Care Res (Hoboken)      2010  ;  62  :  664 – 75 .  
  11.       de Vries-Bouwstra    JK,      Goekoop-Ruiterman    YP,      Verpoort    KN,     et al.     Progression  of 
joint damage in early rheumatoid arthritis: association with   HLA-DRB1 ,  rheumatoid 
factor, and anti-citrullinated protein antibodies in relation to different treatment 
strategies.      Arthritis Rheum      2008  ;  58  :  1293 – 8 .  
  12.       Rönnelid    J,      Wick    MC,      Lampa    J,     et al.       Longitudinal analysis of citrullinated protein/
peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: 
anti-CP status predicts worse disease activity and greater radiological progression.     
  Ann Rheum Dis      2005  ;  64  :  1744 – 9 .  
  13.       Forslind    K,      Ahlmén    M,      Eberhardt    K,     et al.   ;    BARFOT  Study  Group  .    Prediction 
of radiological outcome in early rheumatoid arthritis in clinical practice: role of 
antibodies to citrullinated peptides (anti-CCP).         Ann Rheum Dis      2004  ;  63  :  1090 – 5 .  
  14.       Bukhari    M,      Thomson    W,      Naseem    H,     et al.       The performance of anti-cyclic 
citrullinated peptide antibodies in predicting the severity of radiologic damage in 
inﬂ  ammatory polyarthritis: results from the Norfolk Arthritis Register.         Arthritis Rheum   
  2007  ;  56  :  2929 – 35 .  
  15.       Calin    A,      Elswood    J,      Klouda    PT.      Destructive  arthritis,  rheumatoid  factor,  and 
HLA-DR4. Susceptibility versus severity, a case–control study.         Arthritis Rheum   
  1989  ;  32  :  1221 – 5 .  
  16.       Winchester    R.         The molecular basis of susceptibility to rheumatoid arthritis.         Adv 
Immunol      1994  ;  56  :  389 – 466 .  
  17.       Balsa    A,      Cabezón    A,      Orozco    G,     et al.     Inﬂ   uence  of   HLA DRB1   alleles in the 
susceptibility of rheumatoid arthritis and the regulation of antibodies against 
citrullinated proteins and rheumatoid factor.         Arthritis Res Ther      2010  ;  12  :  R62 .  
  18.       van der Helm-van Mil    AH,      Verpoort    KN,      Breedveld    FC,     et al.     The   HLA-DRB1   shared 
epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies 
and are not an independent risk factor for development of rheumatoid arthritis.     
  Arthritis Rheum      2006  ;  54  :  1117 – 21 .  
  19.       de Vries    RR,      Huizinga    TW,      Toes    RE.      Redeﬁ   ning  the  HLA  and  RA  association:  to  be  or 
not to be anti-CCP positive.         J Autoimmun      2005  ;  25 ( Suppl ): 21 – 5 .  
  20.       Farragher    TM,      Goodson    NJ,      Naseem    H,     et al.       Association of the   HLA-DRB1   gene 
with premature death, particularly from cardiovascular disease, in patients with 
rheumatoid arthritis and inﬂ  ammatory polyarthritis.         Arthritis Rheum      2008  ;  58  :  359 – 69 .  
  21.       Mattey    DL,      Thomson    W,      Ollier    WE,     et al.     Association  of   DRB1   shared epitope 
genotypes with early mortality in rheumatoid arthritis: results of eighteen 
years of followup from the early rheumatoid arthritis study.         Arthritis Rheum   
  2007  ;  56  :  1408 – 16 .  
  22.       Janssens    AC,      Steyerberg    EW,      Jiang    Y,     et al.       Value of the   HLA-DRB1   shared epitope 
for predicting radiographic damage in rheumatoid arthritis depends on the individual 
patient risk proﬁ  le.         J Rheumatol      2006  ;  33  :  2383 – 9 .  
  23.       Farragher    TM,      Lunt    M,      Fu    B,     et al.       Early treatment with, and time receiving, ﬁ  rst 
disease-modifying antirheumatic drug predicts long-term function in patients with 
inﬂ   ammatory  polyarthritis.      Ann Rheum Dis      2010  ;  69  :  689 – 95 .  
  24.       Schmajuk    G,      Schneeweiss    S,      Katz    JN,     et al.       Treatment of older adult patients 
diagnosed with rheumatoid arthritis: improved but not optimal.         Arthritis Rheum   
  2007  ;  57  :  928 – 34 .  
  25.       Tutuncu    Z,      Reed    G,      Kremer    J,     et al.       Do patients with older-onset rheumatoid arthritis 
receive less aggressive treatment?         Ann Rheum Dis      2006  ;  65  :  1226 – 9 .  
  26.       Radovits    BJ,      Kievit    W,      Laan    RF.      Tumour  necrosis  factor-alpha  antagonists  in  the 
management of rheumatoid arthritis in the elderly: a review of their efﬁ  cacy and 
safety.      Drugs Aging      2009  ;  26  :  647 – 64 .    
RA at some point during follow-up. However, some of these 
patients were not classiﬁ  ed as having RA at baseline (33%), and 
when trying to identify predictors for the need to start biological 
therapy in patients with recent onset arthritis it is important to 
include all patients with IP in the analysis. 
  Overall, the factors identiﬁ  ed in this study as predictors for 
receiving (or deciding to prescribe) biological therapy are a combi-
nation of factors associated with severe disease progression such 
as ACPA positivity, SE status, failure on the ﬁ  rst non-  biological 
DMARD and current smoking, plus demographic characteristics 
of the patients such as age and gender. Interestingly, none of these 
factors is included in the National Institute for Health and Clinical 
Excellence guidance for prescribing biological therapies in RA.     
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